Medical Dermatology Specialists

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Psoriasis6 trials
• Atopic dermatitis (eczema)2 trials
• Hidradenitis suppurativa2 trials
• Obesity2 trials
• Melanoma1 trial
• Vitiligo1 trial

Phase

• Phase 38 trials
• Phase 22 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Completed6 trials
• Active, not recruiting4 trials
• Recruiting2 trials

Lead sponsor

• Eli Lilly and Company5 trials
• Janssen Research & Development, LLC2 trials
• Takeda2 trials
• Amgen1 trial
• Medical Dermatology Specialists1 trial
• and 1 more

Running trials

• Recruiting

  A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

  NCT07533019· Phase 2· Eli Lilly and Company· Source

  Contact: Lindsay Ackerman (principal investigator)

• Recruiting

  A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

  NCT06857942· Phase 4· Eli Lilly and Company· Source

  Contact: Lindsay Ackerman (principal investigator)

• Active, not recruiting

  A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

  NCT06799000· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Takeda· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  NCT06143878· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

  NCT06095115· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity1 recruiting
• Psoriasis1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

  NCT06588283· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

  NCT06108544· Phase 3· Takeda· Source

• Completed

  A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06046729· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Completed

  A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

  NCT05369403· Phase 3· Eli Lilly and Company· Source

• Completed

  DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients

  NCT03110159· Phase 1/2· Medical Dermatology Specialists· Source